Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Drug specific antibody present? 126 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 126 reports of Drug specific antibody present have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.1% of all adverse event reports for TOCILIZUMAB.

126
Reports of Drug specific antibody present with TOCILIZUMAB
0.1%
of all TOCILIZUMAB reports
0
Deaths
47
Hospitalizations

How Dangerous Is Drug specific antibody present From TOCILIZUMAB?

Of the 126 reports, 47 (37.3%) required hospitalization, and 17 (13.5%) were considered life-threatening.

Is Drug specific antibody present Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 126 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Drug specific antibody present?

ADALIMUMAB (1,721) INFLIXIMAB (1,600) INFLIXIMAB-DYYB (639) METHOTREXATE (290) NATALIZUMAB (248) VEDOLIZUMAB (197) AGALSIDASE BETA (175) ETANERCEPT (161) AVALGLUCOSIDASE ALFA-NGPT (124) AZATHIOPRINE (120)

Which TOCILIZUMAB Alternatives Have Lower Drug specific antibody present Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Drug specific antibody present Reports All Drugs Causing Drug specific antibody present TOCILIZUMAB Demographics